Overview

Community-led Responses for Elimination: Controlled Trial of Reactive Case Detection Versus Reactive Drug Administration

Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to compare the effectiveness of reactive focal drug administration (RFDA) using dihydroartemisinin+piperaquine (DHAP) versus reactive focal test and treat (RFTAT) using artemether+lumefantrine (AL) as a routine process for identifying and eliminating malaria transmission as measured through achieving zero seropositivity in children under five in Southern Province, Zambia. These two strategies are potential candidates for expanded malaria operational surveillance and elimination for low malaria transmission areas.
Phase:
Phase 4
Details
Lead Sponsor:
PATH
Collaborators:
AKROS Global Health
Ministry of Health, Zambia
Treatments:
Dihydroartemisinin
Piperaquine